Sirios Capital Management L P Sells 7,880 Shares of Lantheus Holdings, Inc. $LNTH

Sirios Capital Management L P cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 46.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,074 shares of the medical equipment provider’s stock after selling 7,880 shares during the quarter. Sirios Capital Management L P’s holdings in Lantheus were worth $465,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Lantheus by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after purchasing an additional 115,338 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Lantheus during the third quarter worth about $65,654,000. TD Asset Management Inc boosted its position in Lantheus by 25.0% in the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock valued at $40,568,000 after buying an additional 158,358 shares during the last quarter. Polaris Capital Management LLC purchased a new stake in Lantheus in the third quarter valued at approximately $32,687,000. Finally, Boston Partners increased its holdings in Lantheus by 30.5% in the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after buying an additional 134,781 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LNTH. Wall Street Zen raised shares of Lantheus from a “hold” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Citizens Jmp increased their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Mizuho boosted their target price on shares of Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Truist Financial increased their price target on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Price Performance

NASDAQ:LNTH opened at $79.49 on Friday. The company has a 50 day moving average price of $70.53 and a 200-day moving average price of $61.74. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $108.91. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of 23.59 and a beta of -0.11. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The firm’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the business earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.